AFMD - Dosing underway in Affimed's early-stage of study of AFM13 in CD30+ lymphomas

Affimed (AFMD) perks 9% premarket after successfully dosing the first patient with allogeneic cord blood-derived natural killer (cbNK) cells preloaded with innate cell engager AFM13 and has moved on to the AFM13 monotherapy phase of the treatment cycle in adult patients with recurrent/refractory CD30-positive lymphomas. This therapy was developed through a research collaboration with The University of Texas MD Anderson Cancer Center. This is the first in human study to combine an NK cell product with an antibody whose primary mechanism is designed to specifically bind and activate NK cells and tumors cells in a bispecific fashion. The study aims to enroll ~30 patients. The primary objective is to establish the safety and the recommended Phase 2 dose of AFM13-preloaded cbNK cells, followed by weekly treatment with intravenous AFM13.Secondary objectives include assessing the overall, complete and partial response rates.This novel combination approach could lay the groundwork for future cellular therapy combinations with Affimed ICE constructs.

For further details see:

Dosing underway in Affimed's early-stage of study of AFM13 in CD30+ lymphomas